Clinical Trial Detail

NCT ID NCT01988896
Title A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

melanoma

lung non-small cell carcinoma

colorectal cancer

Advanced Solid Tumor

Therapies

Atezolizumab + Cobimetinib

Age Groups: adult senior

No variant requirements are available.